HCV Resistance – Where are we today?
Description: Dr. Robert G. Gish discusses HCV Resistance.
At the conclusion of this program, participants will be able to:
• Discuss how Resistance Associated Variants (RAV) affect HCV treatment
• Discuss what clinical trials tell us about resistance testing
• Optimize therapy and understand the role of RAVs in choosing the correct regimen for HCV treatment
ASCLS P.A.C.E.® credits are available to laboratory professionals through October 18, 2016.